--- title: "Microvast Holdings - CW26 | 10-Q: FY2026 Q1 Revenue: USD 60.61 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285994332.md" datetime: "2026-05-11T20:41:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285994332.md) - [en](https://longbridge.com/en/news/285994332.md) - [zh-HK](https://longbridge.com/zh-HK/news/285994332.md) --- # Microvast Holdings - CW26 | 10-Q: FY2026 Q1 Revenue: USD 60.61 M Revenue: As of FY2026 Q1, the actual value is USD 60.61 M. EPS: As of FY2026 Q1, the actual value is USD -0.04. EBIT: As of FY2026 Q1, the actual value is USD -7.089 M. #### Segment Revenue Microvast Holdings, Inc.’s total revenues for the three months ended March 31, 2026, decreased by $55.9 million, or 48.0%, to $60,612 thousand compared to $116,491 thousand in the same period in 2025, primarily due to a 48.9% reduction in sales volume . Revenue by geographic region for the three months ended March 31, 2026, and 2025, respectively, was: **Asia & Pacific:** $17,142 thousand (29%) vs. $50,051 thousand (43%) . China: $14,877 thousand (25%) vs. $44,126 thousand (38%) . Other Asia & Pacific countries: $2,265 thousand (4%) vs. $5,925 thousand (5%) . **Europe:** $43,236 thousand (71%) vs. $60,050 thousand (52%) . Italy: $31,313 thousand (52%) vs. $36,587 thousand (31%) . France: $11,680 thousand (19%) vs. $18,363 thousand (16%) . Other European countries: $243 thousand (0%) vs. $5,100 thousand (5%) . **United States:** $234 thousand (0%) vs. $6,390 thousand (5%) . #### Operational Metrics - **Gross Profit:** Gross profit was $19,156 thousand for Q1 2026, down from $43,016 thousand in the prior year period, with the gross profit margin decreasing to 31.6% from 36.9% due to lower production utilization . - **Cost of Revenues:** Cost of revenues decreased by $32.0 million, or 43.6%, to -$41,456 thousand for Q1 2026, compared to -$73,475 thousand in Q1 2025, mainly due to decreased sales volumes . - **Operating Expenses:** Total operating expenses decreased by $2,074 thousand, or 7.1%, to -$27,093 thousand for Q1 2026, from -$29,167 thousand in the prior year . - **General and Administrative Expenses:** Decreased by $1.2 million, or 8.3%, to -$12,941 thousand . - **Research and Development Expenses:** Increased by $0.6 million, or 6.8%, to -$8,810 thousand, due to the expansion of domestic R&D presence in the U.S. . - **Selling and Marketing Expenses:** Decreased by $1.5 million, or 21.4%, to -$5,342 thousand . - **Subsidy Income:** Decreased from $1,416 thousand in Q1 2025 to $3 thousand in Q1 2026 . - **(Loss) Profit from Operations:** The company reported an operating loss of -$7,934 thousand for Q1 2026, compared to an operating profit of $15,265 thousand in Q1 2025, marking a decrease of $23,199 thousand or -152.0% . - **Net Profit:** Net profit decreased by $13,579 thousand, or -22.0%, to $48,211 thousand for Q1 2026, from $61,790 thousand in Q1 2025 . - **Foreign Exchange (Loss) Gain:** Shifted from a gain of $3,667 thousand in Q1 2025 to a loss of -$6,900 thousand in Q1 2026, primarily due to unfavorable changes in USD and Euro exchange rates relative to RMB . - **Changes in Fair Value of Warrant Liability and Convertible Loan:** Recognized a gain of $63,838 thousand in Q1 2026, compared to $43,160 thousand in Q1 2025, driven by the decrease in the Company’s stock price . #### Cash Flow - **Net cash (used in) generated from operating activities:** Net cash used in operating activities was -$22,796 thousand for Q1 2026, a decrease of $30.0 million compared to $7,169 thousand generated in Q1 2025 . - **Net cash used in investing activities:** Net cash used was -$2,804 thousand in Q1 2026, compared to -$2,332 thousand in Q1 2025, primarily for facility expansion and equipment purchases . - **Net cash generated from financing activities:** Net cash generated was $29,325 thousand in Q1 2026, an increase of $19.8 million from $9,463 thousand in Q1 2025, mainly due to increased proceeds from bank borrowings . #### Unique Metrics - **Sales Volume:** Sales volume decreased by 48.9% from approximately 535.7 MWh for Q1 2025 to 273.9 MWh for Q1 2026 . - **Order Backlog:** The company has an order backlog of $168.7 million, with the majority expected to be fulfilled in 2026 and 2027 . - **Long-lived Assets by Geographic Region (March 31, 2026 vs. December 31, 2025):** - China: $345,751 thousand (66%) vs. $345,148 thousand (66%) . - Europe: $14,577 thousand (3%) vs. $15,311 thousand (3%) . - United States: $161,376 thousand (31%) vs. $159,168 thousand (31%) . #### Future Outlook and Strategy Microvast Holdings, Inc. aims to scale its proprietary battery technologies across high-growth sectors, focusing on electric commercial vehicles and advancing ESS, while shifting commercial priorities towards new commercial vehicle opportunities and a balanced global strategy in Europe and North America to achieve higher gross margins . The company plans to invest in R&D for new products like 290Ah LFP cells and the KAF™ electric powertrain solution for the U.S. school bus market, with commercialization subject to validation and market integration . To address going concern issues, management intends to generate positive net operating cash flow from existing contracts, refinance short-term debt, potentially use its Controlled Equity Offering Sales Agreement for capital, and prioritize capital expenditures towards immediate and profitable commercial vehicle applications . ### Related Stocks - [MVSTW.US](https://longbridge.com/en/quote/MVSTW.US.md) ## Related News & Research - [CEO.CA's Inside the Boardroom: Zefiro Methane Reports Three Straight Profitable Quarters for 2026 | ZEFIF Stock News](https://longbridge.com/en/news/286904988.md) - [Investors shift to dividend stocks as 60/40 model fades](https://longbridge.com/en/news/286677296.md) - [Standex Stock Has Surged 60%. Here’s Why One Fund Still Bought $49 Million Worth](https://longbridge.com/en/news/286955554.md) - [Capstone Reports Q1 2026 Results: Revenue Up 60%, Gross Profit Up 124%, Best Q1 Gross Margin in Four Years | CAPS Stock News](https://longbridge.com/en/news/287057229.md) - [BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts | ONC Stock News](https://longbridge.com/en/news/287198763.md)